A drug used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study has found. Last year, the same scientists reported that the drug -- aprotinin, sold by Bayer AG under the name Trasylol -- raised the risk of kidney failure, heart attacks and strokes. Bayer has responded that the findings are unreliable but that it will "work with regulatory agencies and external experts in the field" to evaluate them.
February 08, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study found.
The researchers said replacing the drug — aprotinin, sold by Bayer AG under the brand name Trasylol — with other, cheaper medications for a year would prevent 10,000 deaths worldwide over the next five years.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Join the Mendocino County District Attorney s Office and work in Mendocino County home to redwoods, vineyards and picturesque coastline. ...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
